Fusion-driven Spindle Cell Rhabdomyosarcomas of Bone and Soft Tissue: A Clinicopathologic and Molecular Genetic Study of 25 Cases.

[1]  A. Folpe,et al.  Rhabdomyosarcoma Arising in Inflammatory Rhabdomyoblastic Tumor: A Genetically Distinctive Subtype of Rhabdomyosarcoma. , 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[2]  Mai Matsumura,et al.  Rhabdomyosarcoma With FUS::TFCP2 Fusion in the Scalp: A Rare Case Report Depicting Round and Spindle cell Morphology , 2022, International journal of surgical pathology.

[3]  M. Lopes,et al.  Rhabdomyosarcoma with TFCP2 Rearrangement or Typical Co-expression of AE1/AE3 and ALK: Report of Three New Cases in the Head and Neck Region and Literature Review , 2022, Head and Neck Pathology.

[4]  Yang Liu,et al.  Clinicopathological features of rhabdomyosarcoma with novel FET::TFCP2 and TIMP3::ALK fusion: report of two cases and literature review , 2022, Histopathology.

[5]  Yangyang Ma,et al.  TFCP2‐rearranged epithelioid and spindle cell rhabdomyosarcoma in the bladder: A rare case in an 8‐year‐old female child , 2022, Pediatric blood & cancer.

[6]  N. Usman,et al.  Case report: EWSR1-TFCP2 in an adolescent represents an extremely rare and aggressive form of intraosseous spindle cell rhabdomyosarcomas , 2022, Cold Spring Harbor molecular case studies.

[7]  C. Antonescu,et al.  Recurrent VGLL3 fusions define a distinctive subset of spindle cell rhabdomyosarcoma with an indolent clinical course and striking predilection for the head and neck , 2022, Genes, chromosomes & cancer.

[8]  C. Nonaka,et al.  Intraosseous rhabdomyosarcoma of the maxilla with TFCP2 fusion: A rare aggressive subtype with predilection for the gnathic bones. , 2022, Oral oncology.

[9]  C. Antonescu,et al.  ZFP64::NCOA3 gene fusion defines a novel subset of spindle cell rhabdomyosarcoma , 2022, Genes, chromosomes & cancer.

[10]  R. Foss,et al.  Epithelioid and Spindle Cell Rhabdomyosarcoma of the Oral Mucosa with FUS Rearrangement , 2022, Head and Neck Pathology.

[11]  C. Chow,et al.  Spindle cell/sclerosing rhabdomyosarcoma with DCTN1::ALK fusion: broadening the molecular spectrum with potential therapeutic implications , 2022, Virchows Archiv.

[12]  A. Folpe.  ‘I Can’t Keep Up!’: an update on advances in soft tissue pathology occurring after the publication of the 2020 World Health Organization classification of soft tissue and bone tumours , 2021, Histopathology.

[13]  Christian A. Ross,et al.  SeekFusion - A Clinically Validated Fusion Transcript Detection Pipeline for PCR-Based Next-Generation Sequencing of RNA , 2021, Frontiers in Genetics.

[14]  E. Montgomery,et al.  Novel fusion genes in spindle cell rhabdomyosarcoma: The spectrum broadens , 2021, Genes, chromosomes & cancer.

[15]  R. Tubbs,et al.  DCTN1-ALK gene fusion in inflammatory myofibroblastic tumor (IMT) of the CNS , 2021, Child's Nervous System.

[16]  C. Antonescu,et al.  Recurrent MEIS1-NCOA2/1 fusions in a subset of low-grade spindle cell sarcomas frequently involving the genitourinary and gynecologic tracts , 2021, Modern Pathology.

[17]  Narasimhan P. Agaram,et al.  Head and neck rhabdomyosarcoma with TFCP2 fusions and ALK overexpression: a clinicopathological and molecular analysis of 11 cases , 2020, Histopathology.

[18]  Jessica L. Davis,et al.  EWSR1-PATZ1-rearranged sarcoma: a report of nine cases of spindle and round cell neoplasms with predilection for thoracoabdominal soft tissues and frequent expression of neural and skeletal muscle markers , 2020, Modern Pathology.

[19]  B. Dickson,et al.  Epithelioid and spindle cell rhabdomyosarcoma with FUS-TFCP2 or EWSR1-TFCP2 fusion: report of two cases , 2020, Virchows Archiv.

[20]  J. Rawwas,et al.  FET(EWSR1)-TFCP2 Rhabdomyosarcoma: An Additional Example of this Aggressive Variant with Predilection for the Gnathic Bones , 2020, Head and Neck Pathology.

[21]  A. Laprie,et al.  The combination of radiotherapy and ALK inhibitors is effective in the treatment of intraosseous rhabdomyosarcoma with FUS‐TFCP2 fusion transcript , 2020, Pediatric blood & cancer.

[22]  B. Haas,et al.  Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods , 2019, Genome Biology.

[23]  J. Desai,et al.  Lack of clinical activity with crizotinib in a patient with FUS rearranged rhabdomyosarcoma with ALK protein overexpression. , 2019, Pathology.

[24]  S. Salas,et al.  A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation , 2019, Modern Pathology.

[25]  S. Sugita,et al.  Spindle cell rhabdomyosarcoma in a lumbar vertebra with FUS-TFCP2 fusion. , 2019, Pathology, research and practice.

[26]  Narasimhan P. Agaram,et al.  Expanding the Spectrum of Intraosseous Rhabdomyosarcoma: Correlation Between 2 Distinct Gene Fusions and Phenotype , 2019, The American journal of surgical pathology.

[27]  C. Antonescu,et al.  Novel MEIS1-NCOA2 Gene Fusions Define a Distinct Primitive Spindle Cell Sarcoma of the Kidney , 2018, The American journal of surgical pathology.

[28]  Narasimhan P. Agaram,et al.  MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification , 2018, Modern Pathology.

[29]  Asha A. Nair,et al.  Spindle cell rhabdomyosarcoma of bone with FUS–TFCP2 fusion: confirmation of a very recently described rhabdomyosarcoma subtype , 2018, Histopathology.

[30]  O. Delattre,et al.  Transcriptomic definition of molecular subgroups of small round cell sarcomas , 2018, The Journal of pathology.

[31]  James R. Anderson,et al.  Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group , 2017, Pediatric blood & cancer.

[32]  J. Wolf,et al.  ALKG1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor , 2017, npj Precision Oncology.

[33]  A. Dutt,et al.  MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes , 2016, Modern Pathology.

[34]  Narasimhan P. Agaram,et al.  A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases , 2015, The American journal of surgical pathology.

[35]  I. Yeh,et al.  Clinical, Histopathologic, and Genomic Features of Spitz Tumors With ALK Fusions , 2015, The American journal of surgical pathology.

[36]  Narasimhan P. Agaram,et al.  Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: Evidence for a common pathogenesis , 2014, Genes, chromosomes & cancer.

[37]  L. Cerroni,et al.  Clinical and Pathologic Findings of Spitz Nevi and Atypical Spitz Tumors With ALK Fusions , 2014, The American journal of surgical pathology.

[38]  C. Fletcher,et al.  Transactivating mutation of the MYOD1 gene is a frequent event in adult spindle cell rhabdomyosarcoma , 2014, The Journal of pathology.

[39]  G. Getz,et al.  Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. , 2014, Cancer discovery.

[40]  M. Rubin,et al.  Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma , 2013, Genes, chromosomes & cancer.

[41]  M. Yaszemski,et al.  Fusion of dynactin 1 to anaplastic lymphoma kinase in inflammatory myofibroblastic tumor. , 2012, Human pathology.

[42]  Lynette M. Smith,et al.  Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: A report from the Children's Oncology Group , 2012, Genes, chromosomes & cancer.

[43]  C. Linardic.  PAX3-FOXO1 fusion gene in rhabdomyosarcoma. , 2008, Cancer letters.

[44]  K. Sakamoto,et al.  Zfp64 participates in Notch signaling and regulates differentiation in mesenchymal cells , 2008, Journal of Cell Science.

[45]  P. Sorensen,et al.  PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  I. Leuschner,et al.  Spindle Cell Variants of Embryonal Rhabdomyosarcoma in the Paratesticular Region: A Report of the Intergroup Rhabdomyosarcoma Study , 1993, The American journal of surgical pathology.

[47]  P. Wuisman,et al.  Spindle cell (leiomyomatous) rhabdomyosarcoma, a rare variant of embryonal rhabdomyosarcoma. , 1993, Pathology, research and practice.

[48]  V. Ninfo,et al.  Spindle Cell Rhabdomyosarcoma: A Prognostically Favorable Variant of Rhabdomyosarcoma , 1992, The American journal of surgical pathology.

[49]  Tindaro M Giardina,et al.  Rhabdomyosarcoma with FUS re-arrangement: additional case in support of a novel subtype. , 2019, Pathology.

[50]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..